Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mariateresa Fulciniti, Ph.D.

Co-Author

This page shows the publications co-authored by Mariateresa Fulciniti and Eugenio Morelli.
Connection Strength

0.639
  1. CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. Methods Mol Biol. 2021; 2348:189-204.
    View in: PubMed
    Score: 0.234
  2. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018 09 06; 132(10):1050-1063.
    View in: PubMed
    Score: 0.197
  3. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep; 2(5):468-483.
    View in: PubMed
    Score: 0.060
  4. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
    View in: PubMed
    Score: 0.057
  5. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018 09; 32(9):1948-1957.
    View in: PubMed
    Score: 0.048
  6. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 06; 15(6):1364-75.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.